Medications
Beta2-AR agonist therapy puts the brakes on oral cancer progression
Affecting almost 600,000 people worldwide every year, and with only a 50% survival rate, oral squamous cell carcinoma (OSCC) is one of the more common and deadly forms of cancer. The poor prognosis of OSCC patients is mainly ...
Dec 4, 2020
0
4